Condition: Lipoma · Submental Fullness · Sponsor: Glonova Pharma Co., Ltd
This study aims to evaluate the safety, efficacy, and pharmacokinetics of Ronkyla Plus, a combinational drug that forms a hydrogel at the injection site, promising a better experience of lipolysis injection for the treatment of superficial lipoma. The study consists of a Part I dose-escalation study to investigate the drug's maximum tolerated dose (MTD) for this indication and a Part II study for evaluating its relative bioavailability in comparison to an FDA-approved lipolysis injection, Kybella.
This description comes directly from the study's public registry record.
Cindy Chen, MS · (+886) 2-2351-1190 · Cindy.Chen@glonova.com.tw
Always discuss trial participation with your own doctor first.
| Cathay General Hospital | Taipei, Da'an District, Taiwan | Recruiting |
| Cathay General Hospital Sijhih Branch | New Taipei City, Sijhih District, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07237425